The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone. We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca’s tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets. Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray; LinkedIn:   / alexander-gray-934a653   Keep up with David Radwaner; LinkedIn:   / david-radwaner-1b496343   Keep up with Tom Brockbank; LinkedIn:   / tom-brockbank-159bb4116     Follow IDEA Pharma On; Website: https://www.ideapharma.com/